Determination of Minimum Inhibitory and Fungicidal Concentrations of Potash Alum Against Clinical Isolates of Candida albicans

Muhammad Irshad                                 PhD

Muhamamd Younas                               FCPS

Asif Ullah Qureshi                                   FDS

Amir Hameed                                           MPH

OBJECTIVE: Candida albicans is an opportunistic pathogen causing oral candidiasis. Commercially available antifungal agents are effective in eliminating C. albicans, however, their toxicity and high cost are undesirable. Potash Alum is a naturally occurring salt with antibacterial and antifungal properties. Therefore, Potash Alum may be effective against C. albicans. Objective: The main objective of this study was to investigate the in vitro susceptibility of C. albicans to Potash Alum.
Swab samples from 19 patients attending the Oral medicine department of Rehman College of Dentistry were transferred to tubes containing Sabouraud Dextrose Broth. After identification of C. albicans by Gram-staining, a solution of 2-5 x 105 CFUs/mL C. albicans was prepared and subjected to MIC and MFC determination by the standard broth microdilution method. Potash alum concentrations of 5, 10 and 20 mg/mL were used. Commercially available Nystatin was used as a positive control.
Our results showed that 10 mg/mL of Potash Alum (PA) solution was able to inhibit growth of most of the clinical isolates of C. albicans. In 5 samples, even 5mg/mL was effective in inhibiting the growth of C. albicans. Potash alum demonstrated fungistatic rather than a fungicidal action against C. albicans.
It is concluded that potash alum has a fungistatic action against C. albicans in vitro. In addition, the optimum in vitro concentration of potash alum solution effective in inhibiting growth of C. albicans was found to be 10mg/mL.
Candida albicans, potash alum, nystatin, antifungal
Irshad M, Younas M, Qureshi AU, Hameed A. Determination of minimum inhibitory and fungicidal concentrations of potash alum against clinical isolates of candida albicans. J Pak Dent Assoc 2020;29(4):235-238.
25 July 2020, Accepted: 04 September 2020
Download PDF